| Literature DB >> 30501965 |
Paul V Fish1, David Steadman2, Elliott D Bayle3, Paul Whiting4.
Abstract
Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target β-amyloid (Aβ) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the 'Aβ hypothesis', there are a number of newer approaches to treat AD with neuroinflammation emerging as a very active area of research based on risk gene analysis. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.Entities:
Keywords: Alzheimer’s disease; Disease modification; Drug discovery pipeline; Neurodegeneration; Neuroinflammation; Symptomatic treatments
Mesh:
Substances:
Year: 2018 PMID: 30501965 DOI: 10.1016/j.bmcl.2018.11.034
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823